Orbifloxacin | CAS# 113617-63-3 | Antibiotic

Orbifloxacin
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 564421

CAS#: 113617-63-3

Description: Orbifloxacin is an antibiotic which is effective against most Gram-negative bacteria, including Enterobacteriaceae and Pseudomonas.

Chemical Structure

Orbifloxacin

CAS# 113617-63-3

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 564421
Name: Orbifloxacin
CAS#: 113617-63-3
Chemical Formula: C19H20F3N3O3
Exact Mass: 395.15
Molecular Weight: 395.382
Elemental Analysis: C, 57.72; H, 5.10; F, 14.42; N, 10.63; O, 12.14

Price and Availability

Size	Price	Availability	Quantity
50mg	USD 215
100mg	USD 355
250mg	USD 590
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Orbax; Orbifloxacin

IUPAC/Chemical Name: 1-Cyclopropyl-7-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-5,6,8-trifluoro-4-oxoquinoline-3-carboxylic acid

InChi Key: QIPQASLPWJVQMH-DTORHVGOSA-N

InChi Code: InChI=1S/C19H20F3N3O3/c1-8-5-24(6-9(2)23-8)17-14(21)13(20)12-16(15(17)22)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6H2,1-2H3,(H,27,28)/t8-,9+

SMILES Code: O=C(C1=CN(C2CC2)C3=C(C(F)=C(F)C(N4C[C@H](C)N[C@H](C)C4)=C3F)C1=O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Product Data:

Product Data

Instruction:

View handling instruction

Biological target:	Orbifloxacin is a synthetic broad-spectrum fluoroquinolone antibiotic which is approved for use in dogs.
In vitro activity:	Orbifloxacin was tested at different concentrations for killing rate against five isolates obtained from pyoderma cases and against a reference strain (Staphylococcus aureus ATCC 29213). Orbifloxacin expressed a concentration-dependent bactericidal activity against the S. aureus reference strain, but a time-dependent bactericidal activity against S. intermedius. Orbifloxacin induced bactericidal effect against the S. intermedius strains tested with concentrations equal to or two times MIC. Reference: Res Vet Sci. 2004 Aug;77(1):67-71. https://pubmed.ncbi.nlm.nih.gov/15120955/
In vivo activity:	Administration of orbifloxacin in E. coli-infected mice modulated the effects of infection on the percentage of phagocyting macrophages, the percentage of NBT-positive cells, and nitric oxide production. Orbifloxacin did not affect the synthesis and release of interleukin-1 by macrophages. Orbifloxacin exerted a modulating effect on the subsets of lymphocytes in thymus, spleen, and mesenteric lymph node cells in noninfected and E. coli-infected mice. Reference: Immunopharmacol Immunotoxicol. 2005;27(3):461-72. https://pubmed.ncbi.nlm.nih.gov/16237956/

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMF	10.0	25.29
	DMF:PBS (pH 7.2) (1:1)	0.5	1.26
	DMSO	3.0	7.65

Preparing Stock Solutions

The following data is based on the product molecular weight 395.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Zhou W, Yang B, Zou Y, Rahman K, Cao X, Lei Y, Lai R, Fu ZF, Chen X, Cao G. Screening of Compounds for Anti-tuberculosis Activity, and in vitro and in vivo Evaluation of Potential Candidates. Front Microbiol. 2021 Jun 30;12:658637. doi: 10.3389/fmicb.2021.658637. PMID: 34276592; PMCID: PMC8278749. 2. Ganière JP, Médaille C, Etoré F. In vitro antimicrobial activity of orbifloxacin against Staphylococcus intermedius isolates from canine skin and ear infections. Res Vet Sci. 2004 Aug;77(1):67-71. doi: 10.1016/j.rvsc.2004.02.002. PMID: 15120955. 3. Szczypka M, Gaweda B, Obmińska-Mrukowicz B. Modulation of cellular immune response by orbifloxacin in noninfected and E. coli-infected mice. Immunopharmacol Immunotoxicol. 2005;27(3):461-72. doi: 10.1080/08923970500241303. PMID: 16237956.
In vitro protocol:	1. Zhou W, Yang B, Zou Y, Rahman K, Cao X, Lei Y, Lai R, Fu ZF, Chen X, Cao G. Screening of Compounds for Anti-tuberculosis Activity, and in vitro and in vivo Evaluation of Potential Candidates. Front Microbiol. 2021 Jun 30;12:658637. doi: 10.3389/fmicb.2021.658637. PMID: 34276592; PMCID: PMC8278749. 2. Ganière JP, Médaille C, Etoré F. In vitro antimicrobial activity of orbifloxacin against Staphylococcus intermedius isolates from canine skin and ear infections. Res Vet Sci. 2004 Aug;77(1):67-71. doi: 10.1016/j.rvsc.2004.02.002. PMID: 15120955.
In vivo protocol:	1. Zhou W, Yang B, Zou Y, Rahman K, Cao X, Lei Y, Lai R, Fu ZF, Chen X, Cao G. Screening of Compounds for Anti-tuberculosis Activity, and in vitro and in vivo Evaluation of Potential Candidates. Front Microbiol. 2021 Jun 30;12:658637. doi: 10.3389/fmicb.2021.658637. PMID: 34276592; PMCID: PMC8278749. 2. Szczypka M, Gaweda B, Obmińska-Mrukowicz B. Modulation of cellular immune response by orbifloxacin in noninfected and E. coli-infected mice. Immunopharmacol Immunotoxicol. 2005;27(3):461-72. doi: 10.1080/08923970500241303. PMID: 16237956.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Shimizu T, Harada K, Manabe S, Tsukamoto T, Ito N, Hikasa Y. Assessment of urinary pharmacokinetics and pharmacodynamics of orbifloxacin in healthy dogs with ex vivo modelling. J Med Microbiol. 2017 May;66(5):616-621. doi: 10.1099/jmm.0.000476. Epub 2017 May 4. PubMed PMID: 28470147.

2: Shimizu T, Harada K. Determination of minimum biofilm eradication concentrations of orbifloxacin for canine bacterial uropathogens over different treatment periods. Microbiol Immunol. 2017 Jan;61(1):17-22. doi: 10.1111/1348-0421.12461. PubMed PMID: 28042660.

3: Santos OM, Freitas JT, Cazedey EC, de Araújo MB, Doriguetto AC. Structure, Solubility and Stability of Orbifloxacin Crystal Forms: Hemihydrate versus Anhydrate. Molecules. 2016 Mar 9;21(3):328. doi: 10.3390/molecules21030328. PubMed PMID: 27005603.

4: Watson MK, Wittenburg LA, Bui CT, Jarosz KA, Gustafson DL, Johnston MS. Pharmacokinetics and bioavailability of orbifloxacin oral suspension in New Zealand White rabbits (Oryctolagus cuniculus). Am J Vet Res. 2015 Nov;76(11):946-51. doi: 10.2460/ajvr.76.11.946. PubMed PMID: 26512539.

5: Harada K, Sasaki A, Shimizu T. Effects of oral orbifloxacin on fecal coliforms in healthy cats: a pilot study. J Vet Med Sci. 2016 Jan;78(1):83-9. doi: 10.1292/jvms.15-0407. Epub 2015 Aug 27. PubMed PMID: 26311787; PubMed Central PMCID: PMC4751121.

6: Dudhatra GB, Kumar A, Awale MM, Kamani DR, Chauhan BN, Patel HB, Mody SK. Determination of orbifloxacin in sheep plasma by high performance liquid chromatography with ultraviolet detection after intravenous and intramuscular administration. J Pharmacol Toxicol Methods. 2013 Jan-Feb;67(1):50-3. doi: 10.1016/j.vascn.2012.11.002. Epub 2012 Dec 8. PubMed PMID: 23231925.

7: Harada K, Shimizu T, Kataoka Y, Takahashi T. Post-antibiotic effect of orbifloxacin against Escherichia coli and Pseudomonas aeruginosa isolates from dogs. Acta Vet Scand. 2012 Mar 20;54:16. doi: 10.1186/1751-0147-54-16. PubMed PMID: 22433170; PubMed Central PMCID: PMC3338406.

8: Tohamy MA. Comparative pharmacokinetics of orbifloxacin in healthy and Pasteurella multocida infected ducks. Br Poult Sci. 2011 Oct;52(5):639-44. doi: 10.1080/00071668.2011.616953. PubMed PMID: 22029792.

9: Marín P, Fernández-Varón E, Escudero E, Vancraeynest D, Cárceles CM. Pharmacokinetic-pharmacodynamic integration of orbifloxacin in rabbits after intravenous, subcutaneous and intramuscular administration. J Vet Pharmacol Ther. 2008 Feb;31(1):77-82. doi: 10.1111/j.1365-2885.2007.00927.x. PubMed PMID: 18177323.

10: Haines GR, Brown MP, Gronwall RR, Merritt KA, Baltzley LK. Pharmacokinetics of orbifloxacin and its concentration in body fluids and in endometrial tissues of mares. Can J Vet Res. 2001 Jul;65(3):181-7. PubMed PMID: 11480524; PubMed Central PMCID: PMC1189673.

Your view history

Orbifloxacin featured